OPEN ACCESS Freely available online

Advances in Pharmacoepidemiology and Drug Safety

Commentary

Brief Note on Nanoparticles for Cancer Drug Delivery

Gopal Vishwas*

Department of Pharmacology, Banaras Hindu University, Varanasi, India

DESCRIPTION

Nanoparticle advancement has recently expanded into a broad range of clinical applications. Nanoparticles were created to address the problems of gene and drug delivery as well as cell heterogeneity in infections. Exactness therapeutics, in which customized intercessions have improved remedial viability, has also been cultivated to combat this patient heterogeneity. Nanoparticle drug delivery systems are engineered technologies that employ nanoparticles to deliver therapeutic agents in a precise and controlled manner. A modern drug delivery system should minimize side effects while reducing dosage and frequency of administration. Nanoparticle advancement, on the other hand, continues to focus on improving conveyance stages with a one-size-fits-all approach.

Nanoparticle-based drug delivery systems have also been shown to aid in the treatment of cancer-related drug resistance. Overexpression of drug efflux transporters, faulty apoptotic pathways, and a hypoxic environment are all factors in cancer drug resistance. Nanoparticles that target these mechanisms have the potential to improve multidrug resistance reversal. Furthermore, as more mechanisms of tumor drug resistance are discovered, nanoparticles are being developed to target these mechanisms. Scientists have only recently begun to look into the role of nanoparticles in immunotherapy, which is becoming increasingly important in cancer treatment. As lipid-based, polymeric, and inorganic nanoparticles are designed in increasingly precise ways, they can begin to be improved for drug delivery in a more personalized manner, helping in the era of precision medication. We discuss cutting-edge nanoparticle plans used in both non-customized and exactness applications in this article, which could be used to improve accuracy treatments. We focus on advancements in nanoparticle plans that overcome heterogeneous conveyance barriers, arguing that careful nanoparticle configuration can improve viability in everyday conveyance applications while enabling custom-made plans for accuracy applications.

Puncture plugs, visual inserts, contact focal points, and visual iontophoresis are examples of cutting-edge innovations for supported and controlled medication discharge. Different intravitreal inserts have been approved as a result of equal efforts for visual medication delivery advancements for the back of the issues. Novel drug delivery technologies, such as nanoparticles, Nano micelles, dendrimers, micro needles, liposomes, and Nano wafers, are increasingly being investigated for front and back messes. Novel methodologies for the noninvasive delivery of strong restorative specialists are on the rise to achieve patient consistency visual iontophoresis. In this article, we look at past achievements, current trends, and future challenges in the field of visual medication delivery. This in-depth analysis also considers the challenges that visual medication delivery systems will face in the future.

The application of nanotechnology to cancer therapy has opened a new era of cancer treatment. NPs of various types, including organic and inorganic NPs, have already been widely used in the clinical treatment of a variety of cancers. NP-based drug delivery systems are associated with improved pharmacokinetics, biocompatibility, tumor targeting, and stability when compared to traditional drugs, while also reducing systemic toxicity and overcoming drug resistance. Chemotherapy, targeted therapy, radiotherapy, hyperthermia, and gene therapy can all benefit from NP-based drugs because of these advantages. Furthermore, Nano carrier delivery systems offer better platforms for combination therapy, which can help overcome drug resistance mechanisms such as efflux transporter overexpression, a defective apoptotic pathway, and a hypoxic tumor microenvironment.

Correspondence to: Dr. Gopal Vishwas, Department of Pharmacology, Banaras Hindu University, Varanasi, India; Email: gopalvishwas@gmail.com

Received: November 27, 2021; **Accepted**: December 11, 2021; **Published**: December 18, 2021

Citation: Vishwas G (2021) Brief note on Nanoparticles for Cancer Drug Delivery. Adv Pharmacoepidemiol Drug Saf.10:257.